Suchergebnisse - "Beksaç, Meral"

PubPharm (21)

1

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma : an indirect treatment comparison

enthalten in: Leukemia & lymphoma | 2024

von Weisel, K. | Dimopoulos, M. | Beksac, M. | +7

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

3

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO) : extended follow up of an open-label, randomised, multicentre, phase 3 trial

enthalten in: The Lancet. Haematology | 2023

von Dimopoulos, M. | Terpos, E. | Boccadoro, M. | +18

4

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2023

von Mateos, M. | Rigaudeau, S. | Basu, S. | +14

5

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Sonneveld, P. | Chanan-Khan, A. | Weisel, K. | +16

CommentIn: J Clin Oncol. 2023 May 10;41(14):2668. - PMID 36940403

6

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab : Results from the ANDROMEDA study

enthalten in: American journal of hematology | 2022

von Sanchorawala, V. | Palladini, G. | Minnema, M. | +31

7

Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab : Patient-reported outcomes from the APOLLO trial

enthalten in: American journal of hematology | 2022

von Terpos, E. | Dimopoulos, M. | Boccadoro, M. | +20

8

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

enthalten in: Bone marrow transplantation | 2022

von Vincent, L. | Gras, L. | Ceballos, P. | +22

9

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Quach, H. | Mateos, M. | +15

CommentIn: Lancet Oncol. 2022 Mar;23(3):e97. - PMID 35240098

10

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

enthalten in: The New England journal of medicine | 2021

von Kastritis, E. | Palladini, G. | Minnema, M. | +148

CommentIn: Nat Rev Rheumatol. 2021 Sep;17(9):510. - PMID 34345020